The AHA, 340B Health, the Maryland Hospital Association and the Mid-Atlantic Association of Community Health Centers June 26 filed an amicus brief in a federal district court in Maryland, defending the state's law protecting 340B pricing for contract pharmacy arrangements. Similar to a brief filed last week in Mississippi, Novartis Pharmaceuticals is also seeking a preliminary injunction against enforcement of the law in Maryland. 

Related News Articles

Headline
A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at…
Headline
Johnson & Johnson Sept. 30 notified the Health Resources and Services Administration that it is ceasing implementation of its proposed 340B rebate model.…
Headline
The Health Resources and Services Administration Sept. 27 sent a final warning letter to Johnson & Johnson urging the company to inform the agency by…
Headline
“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is…
Headline
The Health Resources and Services Administration Sept. 17 told Johnson & Johnson that the company’s publicly announced plans to implement a 340B rebate…
Headline
The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved…